Free Trial
→ New “Trump” currency proposed in DC (From Paradigm Press) (Ad) Buy TYRA Stock  Free TYRA Stock Alerts

Tyra Biosciences (TYRA) Financials

Tyra Biosciences logo
$8.92 +0.31 (+3.60%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$8.93 +0.01 (+0.11%)
As of 04/17/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Tyra Biosciences

Annual Income Statements for Tyra Biosciences

This table shows Tyra Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -55 -69 -86
Consolidated Net Income / (Loss)		 -55 -69 -86
Net Income / (Loss) Continuing Operations		 -55 -69 -86
Total Pre-Tax Income 		-55 -69 -86
Total Operating Income		 -59 -80 -104
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 59 80 104
Selling, General & Admin Expense		 16 17 24
Research & Development Expense		 43 63 80
Total Other Income / (Expense), net		 3.60 11 18
Interest & Investment Income		 3.65 11 18
Basic Earnings per Share		 ($1.32) ($1.62) ($1.51)
Weighted Average Basic Shares Outstanding		 41.88M 42.70M 57.22M
Diluted Earnings per Share		 ($1.32) ($1.62) ($1.51)
Weighted Average Diluted Shares Outstanding		 41.88M 42.70M 57.22M
Weighted Average Basic & Diluted Shares Outstanding		 42.44M 52.52M 53.09M

Quarterly Income Statements for Tyra Biosciences

This table shows Tyra Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -13 -13 -12 -13 -21 -22 -18 -19 -22 -27
Consolidated Net Income / (Loss)		 -13 -13 -12 -13 -21 -23 -18 -19 -24 -26
Net Income / (Loss) Continuing Operations		 -13 -13 -12 -13 -21 -23 -18 -19 -24 -26
Total Pre-Tax Income 		-13 -13 -12 -13 -21 -23 -18 -19 -24 -26
Total Operating Income		 -14 -15 -14 -16 -24 -26 -22 -24 -29 -30
Total Operating Expenses		 14 15 14 16 24 26 22 24 29 30
Selling, General & Admin Expense		 2.73 4.62 3.93 3.85 4.69 4.96 5.12 5.54 5.91 7.54
Research & Development Expense		 11 10 10 12 19 21 17 18 23 22
Total Other Income / (Expense), net		 1.14 2.13 2.45 2.74 2.81 2.80 4.13 4.83 4.59 4.15
Interest & Investment Income		 1.13 2.16 2.45 2.74 2.81 2.80 4.13 4.83 4.59 4.15
Basic Earnings per Share		 ($0.30) ($0.30) ($0.28) ($0.31) ($0.49) ($0.54) ($0.35) ($0.32) ($0.41) ($0.43)
Weighted Average Basic Shares Outstanding		 42.00M 41.88M 42.39M 42.59M 42.87M 42.70M 52.23M 58.67M 58.87M 57.22M
Diluted Earnings per Share		 ($0.30) ($0.30) ($0.28) ($0.31) ($0.49) ($0.54) ($0.35) ($0.32) ($0.41) ($0.43)
Weighted Average Diluted Shares Outstanding		 42.00M 41.88M 42.39M 42.59M 42.87M 42.70M 52.23M 58.67M 58.87M 57.22M
Weighted Average Basic & Diluted Shares Outstanding		 42.20M 42.44M 42.56M 43.01M 43.06M 52.52M 52.54M 52.81M 50.60M 53.09M

Annual Cash Flow Statements for Tyra Biosciences

This table details how cash moves in and out of Tyra Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Change in Cash & Equivalents		 -50 -193 34
Net Cash From Operating Activities		 -50 -50 -70
Net Cash From Continuing Operating Activities		 -50 -50 -70
Net Income / (Loss) Continuing Operations		 -55 -69 -86
Consolidated Net Income / (Loss)		 -55 -69 -86
Depreciation Expense		 0.30 0.36 0.52
Non-Cash Adjustments To Reconcile Net Income		 11 12 17
Changes in Operating Assets and Liabilities, net		 -5.85 6.36 -0.73
Net Cash From Investing Activities		 -0.56 -145 -98
Net Cash From Continuing Investing Activities		 -0.56 -145 -98
Purchase of Property, Plant & Equipment		 -0.56 -0.77 -0.66
Purchase of Investments		 0.00 -144 -264
Sale and/or Maturity of Investments		 0.00 0.00 166
Net Cash From Financing Activities		 0.63 1.54 202
Net Cash From Continuing Financing Activities		 0.63 1.54 202
Issuance of Common Equity		 0.63 1.54 202
Cash Interest Paid		 0.00 0.00 0.00

Quarterly Cash Flow Statements for Tyra Biosciences

This table details how cash moves in and out of Tyra Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 -12 -12 -9.51 -9.29 -17 -158 196 -155 4.40 -12
Net Cash From Operating Activities		 -12 -12 -9.85 -9.62 -17 -14 -22 -10 -18 -20
Net Cash From Continuing Operating Activities		 -12 -12 -9.85 -9.62 -17 -14 -22 -10 -18 -20
Net Income / (Loss) Continuing Operations		 -13 -13 -12 -13 -21 -23 -18 -19 -24 -26
Consolidated Net Income / (Loss)		 -13 -13 -12 -13 -21 -23 -18 -19 -24 -26
Depreciation Expense		 0.08 0.08 0.08 0.09 0.08 0.10 0.12 0.13 0.13 0.14
Non-Cash Adjustments To Reconcile Net Income		 1.02 2.91 2.43 2.53 4.38 2.94 2.89 2.54 5.97 5.52
Changes in Operating Assets and Liabilities, net		 -0.81 -2.08 -0.48 1.04 -0.45 6.26 -6.84 5.77 0.02 0.32
Net Cash From Investing Activities		 -0.05 -0.02 -0.04 -0.04 -0.08 -144 18 -145 22 6.96
Net Cash From Continuing Investing Activities		 -0.05 -0.02 -0.04 -0.04 -0.08 -144 18 -145 22 6.96
Purchase of Property, Plant & Equipment		 -0.05 -0.02 -0.04 -0.04 -0.08 -0.60 -0.14 -0.47 -0.05 -0.01
Purchase of Investments		 - - 0.00 - - -144 -12 -177 -36 -38
Sale and/or Maturity of Investments		 - - 0.00 - - - 30 33 58 45
Net Cash From Financing Activities		 0.36 0.00 0.38 0.37 0.47 0.32 200 0.37 0.74 0.71
Net Cash From Continuing Financing Activities		 0.36 0.00 0.38 0.37 0.47 0.32 200 0.37 0.74 0.71
Issuance of Common Equity		 0.36 0.00 0.38 0.37 0.47 0.32 200 0.37 0.74 0.71

Annual Balance Sheets for Tyra Biosciences

This table presents Tyra Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Total Assets		 266 226 364
Total Current Assets		 257 212 347
Cash & Equivalents		 251 58 92
Short-Term Investments		 0.00 145 249
Prepaid Expenses		 6.08 8.20 6.02
Plant, Property, & Equipment, net		 1.08 1.63 1.65
Total Noncurrent Assets		 7.82 13 14
Other Noncurrent Operating Assets		 7.82 13 14
Total Liabilities & Shareholders' Equity		 266 226 364
Total Liabilities		 8.35 22 20
Total Current Liabilities		 5.70 15 15
Accounts Payable		 1.15 4.66 0.59
Accrued Expenses		 4.42 10 14
Other Current Liabilities		 0.14 0.28 0.41
Total Noncurrent Liabilities		 2.65 6.26 5.81
Other Noncurrent Operating Liabilities		 2.65 6.26 5.81
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 258 204 343
Total Preferred & Common Equity		 258 204 343
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 258 204 343
Common Stock		 354 369 594
Retained Earnings		 -96 -165 -251
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.38 0.77

Quarterly Balance Sheets for Tyra Biosciences

This table presents Tyra Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 276 255 250 238 405 392 381
Total Current Assets		 267 247 241 225 391 379 366
Cash & Equivalents		 263 242 232 216 254 99 104
Short-Term Investments		 - - - - 128 274 256
Prepaid Expenses		 4.26 5.01 8.33 8.98 8.32 4.78 5.48
Plant, Property, & Equipment, net		 1.15 1.05 1.05 1.15 1.59 1.90 1.79
Total Noncurrent Assets		 7.37 7.30 8.21 13 12 12 13
Other Noncurrent Operating Assets		 7.37 7.30 8.21 13 12 12 13
Total Liabilities & Shareholders' Equity		 276 255 250 238 405 392 381
Total Liabilities		 8.23 6.27 11 16 15 16 18
Total Current Liabilities		 5.49 3.68 5.41 10 8.72 10 12
Accounts Payable		 2.75 1.28 1.44 2.31 2.88 1.58 1.17
Accrued Expenses		 2.62 2.26 3.82 7.69 5.47 8.42 11
Other Current Liabilities		 0.13 0.14 0.14 0.15 0.37 0.38 0.40
Total Noncurrent Liabilities		 2.74 2.58 6.04 6.04 6.15 6.04 5.93
Other Noncurrent Operating Liabilities		 2.74 2.58 6.04 6.04 6.15 6.04 5.93
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 268 249 239 222 390 376 362
Total Preferred & Common Equity		 268 249 239 222 390 376 362
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 268 249 239 222 390 376 362
Common Stock		 351 356 359 364 573 578 586
Retained Earnings		 -83 -108 -121 -142 -183 -202 -226
Accumulated Other Comprehensive Income / (Loss)		 - - - - -0.01 -0.18 1.75

Annual Metrics and Ratios for Tyra Biosciences

This table displays calculated financial ratios and metrics derived from Tyra Biosciences' official financial filings.

Metric 2022 2023 2024
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 -124.26% -35.63% -30.24%
EBIT Growth		 -124.19% -35.55% -30.31%
NOPAT Growth		 -124.16% -35.67% -30.31%
Net Income Growth		 -110.41% -24.96% -25.09%
EPS Growth		 30.89% -22.73% 6.79%
Operating Cash Flow Growth		 -111.77% 0.29% -39.16%
Free Cash Flow Firm Growth		 -152.04% -3.79% -47.27%
Invested Capital Growth		 1,586.74% -88.01% 115.64%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -9.49% -15.36% -4.05%
EBIT Q/Q Growth		 -9.50% -15.31% -4.08%
NOPAT Q/Q Growth		 -9.45% -15.31% -4.08%
Net Income Q/Q Growth		 -5.66% -16.78% -3.27%
EPS Q/Q Growth		 -157.14% -17.39% 6.79%
Operating Cash Flow Q/Q Growth		 -6.24% -3.19% -9.51%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.73% -12.38%
Invested Capital Q/Q Growth		 45.57% -87.83% -20.76%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00%
Interest Burden Percent		 93.81% 86.48% 83.01%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -19.77% -29.92% -31.60%
Cash Return on Invested Capital (CROIC)		 -730.20% -1,353.45% -5,900.19%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -19.77% -29.92% -31.60%
Return on Equity Simple (ROE_SIMPLE)		 -21.46% -33.85% -25.20%
Net Operating Profit after Tax (NOPAT)		 -41 -56 -73
NOPAT Margin		 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.09% -5.79% -4.98%
Return On Investment Capital (ROIC_SIMPLE)		 - -27.40% -21.25%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -59 -80 -104
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -59 -80 -104
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 1.24 2.92 2.05
Price to Tangible Book Value (P/TBV)		 1.24 2.92 2.05
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 10.50 495.45 211.66
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -0.99 -0.98 -1.00
Leverage Ratio		 1.02 1.06 1.08
Compound Leverage Factor		 0.96 0.92 0.89
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 22.94 15.42 19.87
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 45.13 13.80 23.81
Quick Ratio		 44.06 13.27 23.40
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -48 -50 -74
Operating Cash Flow to CapEx		 -8,995.53% -6,511.56% -10,508.13%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 6.62 0.79 1.71
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 7.06 -5.82 0.92
Enterprise Value (EV)		 69 393 362
Market Capitalization		 321 596 703
Book Value per Share		 $6.11 $4.74 $6.78
Tangible Book Value per Share		 $6.11 $4.74 $6.78
Total Capital		 258 204 343
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -251 -203 -341
Capital Expenditures (CapEx)		 0.56 0.77 0.66
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.37 -7.13 -8.57
Debt-free Net Working Capital (DFNWC)		 252 196 333
Net Working Capital (NWC)		 252 196 333
Net Nonoperating Expense (NNE)		 14 13 14
Net Nonoperating Obligations (NNO)		 -251 -203 -341
Total Depreciation and Amortization (D&A)		 0.30 0.36 0.52
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($1.32) ($1.62) ($1.51)
Adjusted Weighted Average Basic Shares Outstanding		 41.88M 42.70M 57.22M
Adjusted Diluted Earnings per Share		 ($1.32) ($1.62) ($1.51)
Adjusted Weighted Average Diluted Shares Outstanding		 41.88M 42.70M 57.22M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 42.44M 52.52M 53.09M
Normalized Net Operating Profit after Tax (NOPAT)		 -41 -56 -73
Normalized NOPAT Margin		 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Tyra Biosciences

This table displays calculated financial ratios and metrics derived from Tyra Biosciences' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -105.30% -51.44% 3.58% -3.59% -76.13% -70.55% -55.78% -46.98% -19.25% -15.84%
EBIT Growth		 -105.27% -51.50% 3.44% -3.71% -75.68% -70.30% -55.73% -46.95% -19.37% -15.94%
NOPAT Growth		 -105.56% -51.24% 3.37% -3.80% -75.62% -70.67% -55.73% -46.95% -19.37% -15.94%
Net Income Growth		 -88.30% -29.86% 19.87% 12.08% -69.09% -77.05% -53.13% -40.91% -13.54% -12.01%
EPS Growth		 58.33% -109.01% 22.22% 13.89% -63.33% -80.00% -25.00% -3.23% 16.33% 20.37%
Operating Cash Flow Growth		 -118.93% -32.70% -10.33% 43.99% -40.39% -12.95% -123.70% -6.69% -4.39% -44.77%
Free Cash Flow Firm Growth		 -4,203.92% 0.00% -103.31% 6.34% -2.35% 31.03% 13.47% 7.80% 16.45% -79.20%
Invested Capital Growth		 207.68% 1,586.74% 639.09% 64.42% 43.41% -88.01% 4.63% -63.52% -66.89% 115.64%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 11.81% -10.41% 4.80% -11.75% -49.95% -6.92% 13.05% -5.43% -21.67% -3.86%
EBIT Q/Q Growth		 11.66% -10.35% 4.77% -11.72% -49.64% -6.97% 12.92% -5.42% -21.55% -3.90%
NOPAT Q/Q Growth		 11.56% -10.08% 4.57% -11.72% -49.64% -6.97% 12.92% -5.42% -21.55% -3.90%
Net Income Q/Q Growth		 17.13% -3.09% 7.87% -11.72% -59.37% -7.93% 20.32% -2.80% -28.41% -6.47%
EPS Q/Q Growth		 16.67% 0.00% 6.67% -10.71% -58.06% -10.20% 35.19% 8.57% -28.13% -4.88%
Operating Cash Flow Q/Q Growth		 28.87% 1.90% 17.80% 2.36% -78.32% 21.07% -62.78% 53.43% -74.48% -9.45%
Free Cash Flow Firm Q/Q Growth		 -25.93% 4.05% -4.91% 26.11% -37.62% 35.35% -31.62% 21.27% -24.70% -38.67%
Invested Capital Q/Q Growth		 21.33% 45.57% 7.15% -13.12% 5.83% -87.83% 835.31% -69.70% -3.96% -20.76%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 91.71% 85.67% 82.88% 82.88% 88.27% 89.06% 81.50% 79.47% 83.96% 86.04%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -18.13% -19.77% -19.40% -19.54% -24.17% -29.92% -23.63% -26.32% -28.66% -31.60%
Cash Return on Invested Capital (CROIC)		 0.00% -730.20% -695.48% -882.83% -913.04% -1,353.45% -853.18% -1,496.64% -1,514.62% -5,900.19%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -18.13% -19.77% -19.40% -19.54% -24.17% -29.92% -23.63% -26.32% -28.66% -31.60%
Return on Equity Simple (ROE_SIMPLE)		 -19.56% 0.00% -21.05% -21.19% -26.65% 0.00% -19.35% -21.51% -23.11% 0.00%
Net Operating Profit after Tax (NOPAT)		 -9.55 -11 -10 -11 -17 -18 -16 -16 -20 -21
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.02% -0.86% -0.69% -0.81% -1.83% -2.15% -0.82% -0.74% -1.39% -1.75%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -8.78% - - - -6.06%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -14 -15 -14 -16 -24 -26 -22 -24 -29 -30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -14 -15 -14 -16 -24 -26 -22 -23 -28 -30
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 1.38 1.24 2.74 3.04 2.67 2.92 2.21 2.23 3.43 2.05
Price to Tangible Book Value (P/TBV)		 1.38 1.24 2.74 3.04 2.67 2.92 2.21 2.23 3.43 2.05
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 23.26 10.50 62.10 79.95 57.78 495.45 64.57 207.53 408.41 211.66
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.00 -0.99 -0.99 -0.98 -0.98 -0.98 -0.98 -0.99 -0.99 -1.00
Leverage Ratio		 1.03 1.02 1.03 1.04 1.05 1.06 1.03 1.05 1.06 1.08
Compound Leverage Factor		 0.94 0.88 0.85 0.86 0.93 0.95 0.84 0.83 0.89 0.93
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 27.46 23.48 65.68 38.26 21.87 16.22 35.09 30.91 40.73 20.54
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 48.73 45.13 67.00 44.54 22.14 13.80 44.83 36.46 29.55 23.81
Quick Ratio		 47.95 44.06 65.64 43.00 21.25 13.27 43.88 36.00 29.11 23.40
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -18 -18 -18 -14 -19 -12 -16 -13 -16 -22
Operating Cash Flow to CapEx		 -25,441.67% -57,047.62% -24,017.07% -22,360.47% -20,656.63% -2,244.11% -16,197.06% -2,182.55% -34,419.23% -326,500.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 4.55 6.62 7.09 6.16 6.52 0.79 7.42 2.25 2.16 1.71
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 8.77 7.06 8.40 2.41 1.97 -5.82 0.33 -3.91 -4.36 0.92
Enterprise Value (EV)		 106 69 440 492 377 393 479 466 881 362
Market Capitalization		 369 321 682 725 592 596 861 840 1,241 703
Book Value per Share		 $6.38 $6.11 $5.86 $5.61 $5.17 $4.74 $7.42 $7.16 $6.86 $6.78
Tangible Book Value per Share		 $6.38 $6.11 $5.86 $5.61 $5.17 $4.74 $7.42 $7.16 $6.86 $6.78
Total Capital		 268 258 249 239 222 204 390 376 362 343
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -263 -251 -242 -232 -216 -203 -382 -374 -360 -341
Capital Expenditures (CapEx)		 0.05 0.02 0.04 0.04 0.08 0.60 0.14 0.47 0.05 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.23 0.37 1.33 2.93 -1.17 -7.13 -0.40 -5.60 -6.89 -8.57
Debt-free Net Working Capital (DFNWC)		 262 252 243 235 214 196 382 368 353 333
Net Working Capital (NWC)		 262 252 243 235 214 196 382 368 353 333
Net Nonoperating Expense (NNE)		 2.96 2.38 1.85 2.06 4.38 4.89 2.57 2.23 3.99 4.77
Net Nonoperating Obligations (NNO)		 -263 -251 -242 -232 -216 -203 -382 -374 -360 -341
Total Depreciation and Amortization (D&A)		 0.08 0.08 0.08 0.09 0.08 0.10 0.12 0.13 0.13 0.14
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.30) ($0.30) ($0.28) ($0.31) ($0.49) ($0.54) ($0.35) ($0.32) ($0.41) ($0.43)
Adjusted Weighted Average Basic Shares Outstanding		 42.00M 41.88M 42.39M 42.59M 42.87M 42.70M 52.23M 58.67M 58.87M 57.22M
Adjusted Diluted Earnings per Share		 ($0.30) ($0.30) ($0.28) ($0.31) ($0.49) ($0.54) ($0.35) ($0.32) ($0.41) ($0.43)
Adjusted Weighted Average Diluted Shares Outstanding		 42.00M 41.88M 42.39M 42.59M 42.87M 42.70M 52.23M 58.67M 58.87M 57.22M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 42.20M 42.44M 42.56M 43.01M 43.06M 52.52M 52.54M 52.81M 50.60M 53.09M
Normalized Net Operating Profit after Tax (NOPAT)		 -9.55 -11 -10 -11 -17 -18 -16 -16 -20 -21
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Tyra Biosciences' Financials

When does Tyra Biosciences's fiscal year end?

According to the most recent income statement we have on file, Tyra Biosciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Tyra Biosciences' net income changed over the last 2 years?

Tyra Biosciences' net income appears to be on an upward trend, with a most recent value of -$86.48 million in 2024, rising from -$55.33 million in 2022. The previous period was -$69.13 million in 2023.

What is Tyra Biosciences's operating income?
Tyra Biosciences's total operating income in 2024 was -$104.18 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $104.18 million
How has Tyra Biosciences revenue changed over the last 2 years?

Over the last 2 years, Tyra Biosciences' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Tyra Biosciences have?

Tyra Biosciences' total liabilities were at $20.41 million at the end of 2024, a 5.5% decrease from 2023, and a 144.3% increase since 2022.

How much cash does Tyra Biosciences have?

In the past 2 years, Tyra Biosciences' cash and equivalents has ranged from $58.01 million in 2023 to $251.21 million in 2022, and is currently $91.97 million as of their latest financial filing in 2024.

How has Tyra Biosciences' book value per share changed over the last 2 years?

Over the last 2 years, Tyra Biosciences' book value per share changed from 6.11 in 2022 to 6.78 in 2024, a change of 11.0%.


Related Companies

This page (NASDAQ:TYRA) was last updated on 4/19/2025 by MarketBeat.com Staff
From Our Partners
Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsored
Elon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to Mars
Elon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...
InvestorPlace | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
DOGE Social Security bombshell?
Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...
Altimetry | Sponsored
Trump to redistribute trillions of dollars
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Amazon Shocker
Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...
Stansberry Research | Sponsored
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...
Golden Portfolio | Sponsored
Caught on Camera: Elon Musk’s “Area 51”
You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...
Brownstone Research | Sponsored